Aldesleukin, recombinant interleukin-2, is licensed for use in metastatic renal cell carcinoma at specialist centres. It does not increase longevity but can prompt tumour shrinkage in certain individuals. It is highly toxic, acute problems including pulmonary oedema and hypotension.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.